ArticleCureus2025
Mid-term Results of Core Decompression Combined With Bone Marrow Aspirate Concentrate (BMAC) Injection for Early Osteonecrosis of the Femoral Head: A Prospective, Pilot Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteonecrosis of the femoral head (ONFH) is a chronic, debilitating affliction of the hip, with a high incidence in the employable population, thus posing a significant social and economic burden. To date, total hip arthroplasty (THA) remains the only successful treatment for the late stages of ONFH. Various joint-preserving surgical options have been described for early ONFH, with varying success rates. The study aimed to analyze the functional and radiological outcomes of core decompression (CD) combined with bone marrow aspirate concentrate (BMAC) injection for early ONFH. MATERIAL AND
methodsA total of 30 patients with ONFH, Ficat-Arlet Stage I, IIA, and IIB, underwent CD with BMAC injection under fluoroscopic guidance, followed by a period of protected weight-bearing and physiotherapy. Patients were reviewed at 3, 9, and 15 months to look for improvement in the following parameters: pain on visual analogue scale (VAS), hip range of motion (ROM), weekly analgesic requirement, Harris Hip Score (HHS), and reduction in size of lesion on magnetic resonance imaging (MRI).
resultsThe mean age of the study population was 41.2 ± 6.74 years. Mean VAS scores and HHS significantly improved over time (Friedman's test, p < 0.001). Median weekly analgesic doses reduced from 14 (interquartile range (IQR): 10-18) preoperatively to 5 (IQR: 3-7) at 3 months, 3 (IQR: 1-5) at 9 months, and 2 (IQR: 0-4) at 15 months. Following the intervention, hip abduction and external rotation improved significantly (Friedman's test, p < 0.01). While MRI analysis showed an initial significant reduction in size of the lesion at 3 months (p < 0.01, r = 0.33), subsequent follow-ups showed a significant increase (p < 0.01 at 9 months, r = 0.35; p < 0.05 at 15 months, r = 0.29), suggesting limited durability of radiological improvement or possible disease progression despite initial response. A Kaplan-Meier survival analysis indicated a 30% progression rate to Stage III. Conclusion: While CD with BMAC injection has definite advantages in decreasing pain and improving hip ROM, our results suggest that patients with smaller initial lesions and better baseline function may have a more favorable outcome than those with more widespread involvement of the weight-bearing dome. However, MRI findings and a survival analysis indicated a 30% progression rate to Stage III, raising concerns about the long-term efficacy of this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.